2021
Apobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis and hepatocellular cancer
Blanc V, Riordan JD, Soleymanjahi S, Nadeau J, Nalbantoglu I, Xie Y, Molitor EA, Madison BB, Brunt EM, Mills JC, Rubin DC, Ng I, Ha Y, Roberts LR, Davidson NO. Apobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis and hepatocellular cancer. Journal Of Clinical Investigation 2021, 131 PMID: 33445170, PMCID: PMC7773377, DOI: 10.1172/jci138699.Peer-Reviewed Original ResearchConceptsHuman hepatocellular cancerHigh-fructose dietHepatocellular cancerNonalcoholic fatty liver diseaseFatty liver diseaseExpression of mRNALipogenic gene expressionSpontaneous fibrosisAdvanced fibrosisLiver diseaseLiver functionHepatic steatosisInflammatory pathwaysInflammatory responseFed chowLong-term effectsTissue microarrayHepatic proliferationMRNA expressionFactor overexpressionReduced survivalFibrosisOxidative stressExtracellular matrix organizationSteatosis
2018
The impact of diet‐induced hepatic steatosis in a murine model of hepatic ischemia/reperfusion injury
Liss KHH, McCommis KS, Chambers KT, Pietka TA, Schweitzer GG, Park SL, Nalbantoglu I, Weinheimer CJ, Hall AM, Finck BN. The impact of diet‐induced hepatic steatosis in a murine model of hepatic ischemia/reperfusion injury. Liver Transplantation 2018, 24: 908-921. PMID: 29729104, PMCID: PMC6097916, DOI: 10.1002/lt.25189.Peer-Reviewed Original ResearchConceptsDiet-induced hepatic steatosisSteatotic liversHepatic steatosisReperfusion injuryLiver diseaseMicrovesicular steatosisMurine modelObesity-associated nonalcoholic fatty liver diseaseHepatic ischemia/reperfusion injuryEnd-stage liver diseaseIschemia/reperfusion injuryNonalcoholic fatty liver diseasePlasma alanine aminotransferase levelsAlanine aminotransferase levelsFatty liver diseaseCriteria donor organsInflammatory cytokine concentrationsPotential therapeutic approachHepatic IRISteatotic graftsLiver transplantationAminotransferase levelsCommon indicationNonalcoholic steatohepatitisOrgan failure
2017
Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis
McCommis KS, Hodges WT, Brunt EM, Nalbantoglu I, McDonald WG, Holley C, Fujiwara H, Schaffer JE, Colca JR, Finck BN. Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis. Hepatology 2017, 65: 1543-1556. PMID: 28027586, PMCID: PMC5397348, DOI: 10.1002/hep.29025.Peer-Reviewed Original ResearchConceptsStellate cell activationPeroxisome proliferator-activated receptor γProliferator-activated receptor γNonalcoholic steatohepatitisMitochondrial pyruvate carrier 2Cell activationRodent modelsReceptor γDevelopment of NASHNonalcoholic fatty liver diseaseDose-limiting side effectHepatic stellate cell activationFatty liver diseaseInsulin-sensitizing thiazolidinedionesLiver of miceLiver-specific deletionExpression of markersTrans fatty acidsMetabolic syndromeLiver diseaseHepatocyte dysfunctionHepatic fibrosisLiver fibrosisPharmacologic developmentMouse model
2014
Role of liver biopsy in nonalcoholic fatty liver disease.
Nalbantoglu I, Brunt E. Role of liver biopsy in nonalcoholic fatty liver disease. World Journal Of Gastroenterology 2014, 20: 9026-37. PMID: 25083076, PMCID: PMC4112884, DOI: 10.3748/wjg.v20.i27.9026.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonalcoholic fatty liver diseaseFatty liver diseaseLiver diseaseLiver biopsyPediatric nonalcoholic fatty liver diseaseNASH Clinical Research NetworkLocation of fibrosisSpecific histologic lesionsCardiovascular risk factorsExcess alcohol intakeChronic liver diseaseClinical Research NetworkClinical research trialsLiver biopsy evaluationLimitations of biopsyNon-invasive testingImportant liver diseaseHepatic manifestationNecroinflammatory activityMetabolic syndromeAlcohol intakeHistologic findingsHepatic triglyceridesRisk factorsBiopsy evaluation